发表论文(第一作者或者通讯作者): 1. Ye F, Chen Y, Hoang T, Olson EN, and Lu QR etc, HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nature Neuroscience. 2009 Jul; 12(7):829-38. ISSN: 1097-6256; IF 20 2. Hongwei Gao*, Peirun Bai*, Lin Xiao, Mengjia Sheng, Feng Ye*, Hong Bu*. MED16 affects 131I iodine sensitivity by regulating NIS through the TGF β pathway in Papillary thyroid cancer. J. Biol. Chem. 2020 Jul 31;295(31):10726-10740. ISSN: 0021-9258; 3. Yang L, Fu B, Li Y, Liu Y, Huang W, Feng S, Xiao L, Sun L, Deng L, Zheng X, Ye F*, Bu H. Prediction model of the response to neoadjuvant chemotherapy in breast cancers by a Naive Bayes algorithm.Comput Methods Programs Biomed. 2020 Aug;192:105458. doi: 10.1016/j.cmpb.2020.105458. ISSN: 0169-2607 4. Jiang R, Zhang B, Teng X, Hu P, Xu S, Zheng Z, Liu R, Tang T, Ye F*. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients. Sci Rep. 2020 Feb 7;10(1):2070. doi: 10.1038/s41598-020-58819-5. ISSN: 2045-2322 5. Pu T, Shen M, Li S, Yang L, Gao H, Xiao L, Zhong X, Zheng H, Liu Y, Ye F*, Bu H. Repression of miR-135b-5p promotes metastasis of early-stage breast cancer by regulating downstream target SDCBP. Lab Invest. 2019 Sep;99(9):1296-1308. doi: 10.1038/s41374-019-0258-1. ISSN: 0023-6837; 6. Qiu Y, Wang L, Zhong X, Li L, Chen F, Xiao L, Liu F, Fu B, Zheng H, Ye F, Bu H. A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer. BMC Cancer. 2019 Jul 24;19(1):729. ISSN: 1471-2407; 7. Feng Ye, Hongwei Gao, Lin Xiao, Zhixiang Zuo, Yueping Liu, Qi Zhao, Huijiao Chen, Weiyi Feng, Bo Fu, Linyong Sun, Xiaolin Jiang, Du He, He Jiang, Mei Yang, Li Li, Fei Chen, Xiang Liu, Shuang Li, Zhihui Li, Yong Jiang, Liang Cheng, Hong Bu. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma. Int. J. Cancer. 2019 Mar 15;144(6):1321-1330. ISSN: 0020-7136; 8. Feng Ye, Hongwei Gao, Lin Xiao, Hong Ding, Zhouyang Huang, Yong Jiang, Liang Cheng, Hong Bu. Reply to Cirello et al. “Absence of the MAP2K5 germline variants c.G961A and c. T1100C in a wide series of familial non-medullary thyroid carcinoma Italian families.” Int. J. Cancer. Int J Cancer. 2019 Jul 15;145(2):601-602. ISSN: 0020-7136; 9. Wang Y, Liu H, Hou Y, Zhou X, Liang L, Zhang Z, Shi H, Xu S, Hu P, Zheng Z, Liu R, Tang T, Ye F*, Liang Z, Bu H. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. Virchows Arch. 2018 Jun;472(6):959-968. ISSN: 0945-6317 10. Mengjia Shen, Libo Yang, Ting Lei, Lin Xiao, Li Li, Peichuan Zhang, Weiyi Feng, Feng Ye*, Hong Bu. BRCA1/2 mutation spectrum in Chinese early-onset breast cancer. Transl Cancer Res. 2019;8(2):483-490. ISSN: 2218-676X 11. Tianjie Pu, Xiaorong Zhong, Ling Deng, Shi Li, Yan Qiu, Yueping Liu, Hong Zheng, Feng Ye*, Hong Bu: Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study. Int J Clin Exp Pathol 2018;11(5):2665-2674. ISSN: 1936-2625 12. Guo P, Pu T, Chen S, Qiu Y, Zhong X, Zheng H, Chen L, Bu H, Ye F*. Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome. Oncol Lett. 2017 Dec;14(6):6562-6570. ISSN: 1792-1074 13. Ye F, Zhong X, Qiu Y, Yang L, Wei B, Zhang Z, Bu H. CD49f Can Act as a Biomarker for Local or Distant Recurrence in Breast Cancer. J Breast Cancer. 2017 Jun;20(2):142-149. ISSN: 1738-6756 14. Yang libo; Wang Yujia; Shi Yujun; Bong Bu; Feng Ye*. Deletionof SIP1 promotes liver regenerationand lipid accumulation. Pathol Res Pract. 2016 May;212(5):421-5. 15. Feng Ye, Yan Qiu, Li Li, Libo Yang, Fei Cheng, Hongying Zhang, Bing Wei, Zhang Zhang, Linyong Sun, Hong Bu. The Presence of EpCAM/CD49 Cells in Breast Cancer Is Associated with a Poor Clinical Outcome. J Breast Cancer. 2015 Sep;18(3):242-248. ISSN: 1738-6756 16. Yang LB, Sun LY, Jiang Y, Tang Y, Li ZH, Zhang HY, Bu H, Ye F*. The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients. Int J Endocrinol. 2015;2015:642046. ISSN: 1687-8337 17. Qiu Yan, Pu Tianjie, Guo Peng, Wei Bing, Zhang Zhang, Zhang Hongying, Zhong Xiaorong, Zheng Hong, Chen Lina, Bu Hong, Ye Feng*. ALDH+/CD44+ cells in breast cancer are associated with worse prognosis and poor clinical outcome. EXP MOL PATHOL. 2015 Dec 11;100(1):145-150. ISSN: 0014-4800 18. Ye F, Lu X, Lu B, Wang J, Shi Y, Zhang L, Chen J, Li Y, Bu H. A long-term evaluation of osteoinductive HA/beta-TCP ceramics in vivo: 4.5 years study in pigs. J Mater Sci Mater Med. 2007; 18: 2173-8 . 19. 韦晓霞,姜瑞瑞,雷婷,叶丰*,步宏。RT-qPCR法定量检测乳腺癌FFPE样本ER、PR、HER2、Ki-67表达的初步分析。临床与实验病理学杂志,2018,34(9):968-971. 20. 姜瑞瑞,王亚健,滕晓东,叶丰*等。FFPE样本不同二代测序平台性能比较.中华病理学杂志。2018,47(8) : 591-596. ISSN: 0529-5807 21. 叶丰,陈昱,何度,简书玉,郑可,李甘地,步宏*. 应用荧光定量聚合酶链式反应对疑似结合组织的DNA分析. 中华病理学杂志. 2013年8月第42卷第8期. 1-4. ISSN: 0529-5807 22. 叶丰,吴焕文,梁智勇*,步宏*. 临床分子病理实验室二代基因测序检测专家共识. 中华病理学杂志. 2017,46(3):145-147. ISSN: 0529-5807 23. 吴焕文,叶丰,梁智勇*,步宏*. BRCA数据解读中国专家共识. 中华病理学杂志. 2017,46(5): 293-297. ISSN: 0529-5807 国家发明专利已授权: 1. 一种检测石蜡切片组织中结核分枝杆菌复合体的试剂盒和方法(专利号:201510323866.0 叶丰 聂玲 孙林雍) 2. 一种预测乳腺癌复发的试剂盒(专利号:201710922693.3 叶丰 郑鸿 步宏,授权日:2019.7.26) 3. 一种检测人类C-Kit基因9号外显子突变的诊断试剂盒和方法(专利号:201610446425.4 叶丰 陈卉娇 步宏;授权日:2020.1.24) 4. 一种检测人类C-Kit基因13号外显子突变的诊断试剂盒和方法(专利号:201610437150.8 叶丰 肖林 步宏;授权日:2019.6.25) 5. 一种检测人类C-Kit基因11号外显子突变的诊断试剂盒和方法(专利号:201610440446.5 肖林 叶丰 陈卉娇;授权日:2019.7.19) 获得资助课题: 1. CSCO(中国临床肿瘤学会,Y-HR2019-0310,甲状腺癌I131治疗不敏感患者促进剂的优化及临床前试验,2021.1-2022.12,15万,负责人 2. 省委组织部第二批“天府万人计划·科技菁英”专项资金 20万 3. 华西医院临床孵化项目,2020HXFH009,家族性甲状腺非髓样癌临床队列的建立及分子分型和诊断试剂盒开发,2020.6.1-2023.5.31,50万,负责人 4. 国家自然科学基金(面上项目),81972498, MEK5胚系变异抑制细胞自噬并激活MAPK信号通路促进甲状腺非髓样癌发生的机制研究,2020.1.1-2023.12.31,55万,负责人 5. 四川省科技厅重点研发项目(重大科技专项,2019YFS0324 ),甲状腺癌遗传因素研究及防控方案探索,2019.1.1-2020.12.31,20万,负责人 6. 成都市科技局技术创新研发项目(2018-YF05-01177-SN),家族性甲状腺非髓样癌易感基因MAP2K5致病变异鉴定及临床应用转化研究,2018/9-2019/8, 10万,负责人 7. 四川省科技厅计划项目(重点研发项目),2017SZ0005,应用多模态方法,建立三阴乳腺癌预后与疗效预判体系,2017/3-2020/2,300万,子课题负责人到账60万 8. 四川省科技厅应用基础研究(面上项目),基于多基因结合临床病理特征的食管鳞癌(p0T3N0M0)复发风险评估模型研究(2018JY0277),2018.1-2019.12,10万,子课题负责人到账5万 9. 国家自然科学基金(青年基金),31000601,SIP1基因协同多个信号通路调控肝再生向肝再生终止转化的研究, 2011/01-2013/12,21万元,已结题,主持 10. 胃肠道间质瘤基因检测快速诊断试剂盒的研制,16PJ335, 2016.6—2018.5,0.5万, 省卫计委科研项目,主持 11. 四川大学优秀青年学者科研基金(A类),2012SCU04A14,组蛋白去乙酰化酶在肝再生中的作用及机制研究,2012/03-2014/12, 20万元, 已结题,主持 12. 国家863计划军口项目(秘密等级:秘密),(建七666)JG2011091-C,项目名称XXX , 2011/10-2012/6, 5万元, 已结题,主持 13. 上海鹍远基因生物技术有限公司横向课题,HX-H1606061,1000例肺癌/结直肠癌患者石蜡包埋组织二代测序生物信息结果分析、统计与SANGER法验证研究,2016.7---2017.4, 15万,主持 14. 北京雅康博生物技术公司横向课题, HX-H1611124 (卡号312170052),FFPE样本结核分枝杆菌检测的验证研究,2017.3-2018.3. 5万, 主持 15. 上海鹍远基因生物技术有限公司横向课题,HX-1606061(补)(卡号312160362),1000例肺癌/结直肠癌患者石蜡包埋组织二代测序生物信息结果分析、统计与SANGER法验证研究(二期),2016.7---2018.3, 10万,主持 16. 上海鹍远基因生物技术有限公司横向课题,HX-H1704049(卡312170272),FFPE样本NGS后的一代的多方法验证研究,2017.3---2019.12, 20万,主持 17. 北京迈基诺基因科技股份有限公司横向课题,HX-H1710136,人类肿瘤多基因变异联合检测试剂盒(捕获测序法)临床意义研究,2017.8-2018.12,10万,主持 |